Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company ... Lilly has a robust pipeline led by its recently FDA-approved and launched treatment for Alzheimer's disease, Donanemab, sold as Kisunla. Mirikizumab is a treatment for Crohn's disease ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is in good financial shape but investors may be worried about its high valuation.